Drugs / Thymoglobulin®
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02505893 | Apr 2015 → May 2018 | type 1 diabetes mellitus | Ospedale San Raffaele | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Thymoglobulin | “Thymoglobulin® (ATG)” NCT02505893 ↗ |
| Known as | ATG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02505893 ↗ |
| Route | Intravenous | “ATG will be administered IV (central vein) at a total dose of 6 mg/kg up to day 6 post-transplant” NCT02505893 ↗ |